DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Thioguanine |
DM7NKEV
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Thioguanine. |
Acute myeloid leukaemia [2A60]
|
[10] |
Uracil mustard |
DMHL7OB
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Uracil mustard. |
Acute myeloid leukaemia [2A60]
|
[10] |
Midostaurin |
DMI6E0R
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Midostaurin. |
Acute myeloid leukaemia [2A60]
|
[10] |
Gemtuzumab ozogamicin |
DMJ2O7B
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Gemtuzumab ozogamicin. |
Acute myeloid leukaemia [2A60]
|
[10] |
Idarubicin |
DMM0XGL
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Idarubicin. |
Acute myeloid leukaemia [2A60]
|
[10] |
Daunorubicin |
DMQUSBT
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Daunorubicin. |
Acute myeloid leukaemia [2A60]
|
[10] |
Oliceridine |
DM6MDCF
|
Moderate |
Altered metabolism of Etanercept due to Oliceridine alters the formation of CYP450 enzymes. |
Acute pain [MG31]
|
[8] |
Siltuximab |
DMGEATB
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Siltuximab. |
Anemia [3A00-3A9Z]
|
[10] |
Nifedipine |
DMSVOZT
|
Moderate |
Altered metabolism of Etanercept due to Nifedipine alters the formation of CYP450 enzymes. |
Angina pectoris [BA40]
|
[8] |
Alprazolam |
DMC7XDN
|
Moderate |
Altered metabolism of Etanercept due to Alprazolam alters the formation of CYP450 enzymes. |
Anxiety disorder [6B00-6B0Z]
|
[8] |
Methylphenobarbital |
DMDSWAG
|
Moderate |
Altered metabolism of Etanercept due to Methylphenobarbital alters the formation of CYP450 enzymes. |
Anxiety disorder [6B00-6B0Z]
|
[12] |
Clobazam - Lundbeck |
DMW1OQ0
|
Moderate |
Altered metabolism of Etanercept due to Clobazam - Lundbeck alters the formation of CYP450 enzymes. |
Anxiety disorder [6B00-6B0Z]
|
[8] |
Budesonide |
DMJIBAW
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Budesonide. |
Asthma [CA23]
|
[10] |
Aminophylline |
DML2NIB
|
Moderate |
Altered metabolism of Etanercept due to Aminophylline alters the formation of CYP450 enzymes. |
Asthma [CA23]
|
[8] |
Roflumilast |
DMPGHY8
|
Moderate |
Additive immunosuppressive effects by the combination of Etanercept and Roflumilast. |
Asthma [CA23]
|
[8] |
Dupilumab |
DMOAD2Y
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Dupilumab. |
Atopic eczema [EA80]
|
[10] |
Linezolid |
DMGFPU2
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Linezolid. |
Bacterial infection [1A00-1C4Z]
|
[10] |
Temozolomide |
DMKECZD
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Temozolomide. |
Brain cancer [2A00]
|
[10] |
Lomustine |
DMMWSUL
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Lomustine. |
Brain cancer [2A00]
|
[10] |
Eribulin |
DM1DX4Q
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Eribulin. |
Breast cancer [2C60-2C6Y]
|
[10] |
Talazoparib |
DM1KS78
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Talazoparib. |
Breast cancer [2C60-2C6Y]
|
[10] |
Ixabepilone |
DM2OZ3G
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Ixabepilone. |
Breast cancer [2C60-2C6Y]
|
[10] |
LY2835219 |
DM93VBZ
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and LY2835219. |
Breast cancer [2C60-2C6Y]
|
[10] |
Pralatrexate |
DMAO80I
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Pralatrexate. |
Breast cancer [2C60-2C6Y]
|
[10] |
Palbociclib |
DMD7L94
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Palbociclib. |
Breast cancer [2C60-2C6Y]
|
[10] |
Mitomycin |
DMH0ZJE
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Mitomycin. |
Breast cancer [2C60-2C6Y]
|
[10] |
Thiotepa |
DMIZKOP
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Thiotepa. |
Breast cancer [2C60-2C6Y]
|
[10] |
Cabazitaxel |
DMPAZHC
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Cabazitaxel. |
Breast cancer [2C60-2C6Y]
|
[10] |
Bosutinib |
DMTI8YE
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Bosutinib. |
Breast cancer [2C60-2C6Y]
|
[10] |
Trastuzumab |
DMZQOUX
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Trastuzumab. |
Breast cancer [2C60-2C6Y]
|
[10] |
Atorvastatin |
DMF28YC
|
Moderate |
Altered metabolism of Etanercept due to Atorvastatin alters the formation of CYP450 enzymes. |
Cardiovascular disease [BA00-BE2Z]
|
[8] |
Corticotropin |
DMP9TWZ
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Corticotropin. |
Chronic kidney disease [GB61]
|
[10] |
Irinotecan |
DMP6SC2
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Irinotecan. |
Colorectal cancer [2B91]
|
[10] |
Oxaliplatin |
DMQNWRD
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Oxaliplatin. |
Colorectal cancer [2B91]
|
[10] |
Aflibercept |
DMT3D5I
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Aflibercept. |
Colorectal cancer [2B91]
|
[10] |
Capecitabine |
DMTS85L
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Capecitabine. |
Colorectal cancer [2B91]
|
[10] |
Drospirenone |
DM1A9W3
|
Moderate |
Altered metabolism of Etanercept due to Drospirenone alters the formation of CYP450 enzymes. |
Contraceptive management [QA21]
|
[8] |
Levonorgestrel |
DM1DP7T
|
Moderate |
Altered metabolism of Etanercept due to Levonorgestrel alters the formation of CYP450 enzymes. |
Contraceptive management [QA21]
|
[8] |
Etonogestrel |
DMKA8J4
|
Moderate |
Altered metabolism of Etanercept due to Etonogestrel alters the formation of CYP450 enzymes. |
Contraceptive management [QA21]
|
[8] |
Norgestimate |
DMYP4XC
|
Moderate |
Altered metabolism of Etanercept due to Norgestimate alters the formation of CYP450 enzymes. |
Contraceptive management [QA21]
|
[12] |
Lidocaine |
DML4ZOT
|
Moderate |
Altered metabolism of Etanercept due to Lidocaine alters the formation of CYP450 enzymes. |
Corneal disease [9A76-9A78]
|
[8] |
Nimodipine |
DMQ0RKZ
|
Moderate |
Altered metabolism of Etanercept due to Nimodipine alters the formation of CYP450 enzymes. |
Coronary vasospastic disease [BA85]
|
[8] |
Oxtriphylline |
DMLHSE3
|
Moderate |
Altered metabolism of Etanercept due to Oxtriphylline alters the formation of CYP450 enzymes. |
Cough [MD12]
|
[8] |
Methadone |
DMTW6IU
|
Moderate |
Altered metabolism of Etanercept due to Methadone alters the formation of CYP450 enzymes. |
Cough [MD12]
|
[8] |
Mycophenolic acid |
DMRBMAU
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Mycophenolic acid. |
Crohn disease [DD70]
|
[10] |
Rivaroxaban |
DMQMBZ1
|
Moderate |
Altered metabolism of Etanercept due to Rivaroxaban alters the formation of CYP450 enzymes. |
Deep vein thrombosis [BD71]
|
[8] |
Polatuzumab vedotin |
DMF6Y0L
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Polatuzumab vedotin. |
Diffuse large B-cell lymphoma [2A81]
|
[10] |
Lisocabtagene maraleucel |
DMP45ME
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Lisocabtagene maraleucel. |
Diffuse large B-cell lymphoma [2A81]
|
[10] |
Axicabtagene ciloleucel |
DMYHN59
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Axicabtagene ciloleucel. |
Diffuse large B-cell lymphoma [2A81]
|
[10] |
PMID27977313-Compound-29 |
DMIF7KG
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and PMID27977313-Compound-29. |
Discovery agent [N.A.]
|
[10] |
PMID28870136-Compound-48 |
DMPIM9L
|
Moderate |
Altered metabolism of Etanercept due to PMID28870136-Compound-48 alters the formation of CYP450 enzymes. |
Discovery agent [N.A.]
|
[8] |
Oestradiol valerate and dienogest |
DMZK0FQ
|
Moderate |
Altered metabolism of Etanercept due to Oestradiol valerate and dienogest alters the formation of CYP450 enzymes. |
Endometriosis [GA10]
|
[12] |
Diazepam |
DM08E9O
|
Moderate |
Altered metabolism of Etanercept due to Diazepam alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[8] |
Primidone |
DM0WX6I
|
Moderate |
Altered metabolism of Etanercept due to Primidone alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[8] |
Mephenytoin |
DM5UGDK
|
Moderate |
Altered metabolism of Etanercept due to Mephenytoin alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[8] |
Ethosuximide |
DMDZ9LT
|
Moderate |
Altered metabolism of Etanercept due to Ethosuximide alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[8] |
Phenytoin |
DMNOKBV
|
Moderate |
Altered metabolism of Etanercept due to Phenytoin alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[8] |
Fosphenytoin |
DMOX3LB
|
Moderate |
Altered metabolism of Etanercept due to Fosphenytoin alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[8] |
Clonazepam |
DMTO13J
|
Moderate |
Altered metabolism of Etanercept due to Clonazepam alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[8] |
Phenobarbital |
DMXZOCG
|
Moderate |
Altered metabolism of Etanercept due to Phenobarbital alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[8] |
Carbamazepine |
DMZOLBI
|
Moderate |
Altered metabolism of Etanercept due to Carbamazepine alters the formation of CYP450 enzymes. |
Epilepsy/seizure [8A61-8A6Z]
|
[8] |
Nicardipine |
DMCDYW7
|
Moderate |
Altered metabolism of Etanercept due to Nicardipine alters the formation of CYP450 enzymes. |
Essential hypertension [BA00]
|
[8] |
Bay 80-6946 |
DMLOS5R
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Bay 80-6946. |
Follicular lymphoma [2A80]
|
[10] |
Avapritinib |
DMK2GZX
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Avapritinib. |
Gastrointestinal stromal tumour [2B5B]
|
[10] |
177Lu-DOTATATE |
DMT8GVU
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and 177Lu-DOTATATE. |
Hepatitis virus infection [1E50-1E51]
|
[10] |
Procarbazine |
DMIK367
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Procarbazine. |
Hodgkin lymphoma [2B30]
|
[10] |
Bleomycin |
DMNER5S
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Bleomycin. |
Hodgkin lymphoma [2B30]
|
[10] |
Brentuximab vedotin |
DMWLC57
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Brentuximab vedotin. |
Hodgkin lymphoma [2B30]
|
[10] |
Simvastatin |
DM30SGU
|
Moderate |
Altered metabolism of Etanercept due to Simvastatin alters the formation of CYP450 enzymes. |
Hyper-lipoproteinaemia [5C80]
|
[8] |
Lovastatin |
DM9OZWQ
|
Moderate |
Altered metabolism of Etanercept due to Lovastatin alters the formation of CYP450 enzymes. |
Hyper-lipoproteinaemia [5C80]
|
[8] |
Nisoldipine |
DM7ISKJ
|
Moderate |
Altered metabolism of Etanercept due to Nisoldipine alters the formation of CYP450 enzymes. |
Hypertension [BA00-BA04]
|
[8] |
Levamlodipine |
DM92S6N
|
Moderate |
Altered metabolism of Etanercept due to Levamlodipine alters the formation of CYP450 enzymes. |
Hypertension [BA00-BA04]
|
[8] |
Isradipine |
DMA5XGH
|
Moderate |
Altered metabolism of Etanercept due to Isradipine alters the formation of CYP450 enzymes. |
Hypertension [BA00-BA04]
|
[8] |
Amlodipine |
DMBDAZV
|
Moderate |
Altered metabolism of Etanercept due to Amlodipine alters the formation of CYP450 enzymes. |
Hypertension [BA00-BA04]
|
[8] |
Felodipine |
DMOSW35
|
Moderate |
Altered metabolism of Etanercept due to Felodipine alters the formation of CYP450 enzymes. |
Hypertension [BA00-BA04]
|
[8] |
Fludrocortisone |
DMUDIR8
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Fludrocortisone. |
Hypo-osmolality/hyponatraemia [5C72]
|
[10] |
Triazolam |
DMETYK5
|
Moderate |
Altered metabolism of Etanercept due to Triazolam alters the formation of CYP450 enzymes. |
Insomnia [7A00-7A0Z]
|
[8] |
Olaratumab |
DMNYOIX
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Olaratumab. |
Kaposi sarcoma [2B57]
|
[10] |
Methotrexate |
DM2TEOL
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Methotrexate. |
Leukaemia [2A60-2B33]
|
[10] |
Nelarabine |
DMB6VEG
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Nelarabine. |
Leukaemia [2A60-2B33]
|
[10] |
DTI-015 |
DMXZRW0
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and DTI-015. |
Liver cancer [2C12]
|
[10] |
Denosumab |
DMNI0KO
|
Moderate |
Additive immunosuppressive effects by the combination of Etanercept and Denosumab. |
Low bone mass disorder [FB83]
|
[13] |
Brigatinib |
DM7W94S
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Brigatinib. |
Lung cancer [2C25]
|
[10] |
Lurbinectedin |
DMEFRTZ
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Lurbinectedin. |
Lung cancer [2C25]
|
[10] |
Osimertinib |
DMRJLAT
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Osimertinib. |
Lung cancer [2C25]
|
[10] |
Belimumab |
DM3OBQF
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Belimumab. |
Lupus erythematosus [4A40]
|
[10] |
Primaquine |
DMWQ16I
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Primaquine. |
Malaria [1F40-1F45]
|
[10] |
Inotuzumab ozogamicin |
DMAC130
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Inotuzumab ozogamicin. |
Malignant haematopoietic neoplasm [2B33]
|
[10] |
Rituximab |
DM1YVZT
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Rituximab. |
Malignant haematopoietic neoplasm [2B33]
|
[10] |
Tositumomab |
DMMYZ3D
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Tositumomab. |
Malignant haematopoietic neoplasm [2B33]
|
[10] |
Fludarabine |
DMVRLT7
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Fludarabine. |
Malignant haematopoietic neoplasm [2B33]
|
[10] |
Pentostatin |
DM0HXDS
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Pentostatin. |
Mature B-cell leukaemia [2A82]
|
[10] |
Ofatumumab |
DM295PR
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Ofatumumab. |
Mature B-cell leukaemia [2A82]
|
[10] |
Obinutuzumab |
DM3BVAE
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Obinutuzumab. |
Mature B-cell leukaemia [2A82]
|
[10] |
Cladribine |
DM3JDRP
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Cladribine. |
Mature B-cell leukaemia [2A82]
|
[8] |
Idelalisib |
DM602WT
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Idelalisib. |
Mature B-cell leukaemia [2A82]
|
[10] |
GDC-0199 |
DMH0QKA
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and GDC-0199. |
Mature B-cell leukaemia [2A82]
|
[10] |
Chlorambucil |
DMRKE63
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Chlorambucil. |
Mature B-cell leukaemia [2A82]
|
[10] |
Alemtuzumab |
DMZL3IV
|
Moderate |
Additive immunosuppressive effects by the combination of Etanercept and Alemtuzumab. |
Mature B-cell leukaemia [2A82]
|
[14] |
Acalabrutinib |
DM7GCVW
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Acalabrutinib. |
Mature B-cell lymphoma [2A85]
|
[10] |
Clofarabine |
DMCVJ86
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Clofarabine. |
Mature B-cell lymphoma [2A85]
|
[10] |
Blinatumomab |
DMGECIJ
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Blinatumomab. |
Mature B-cell lymphoma [2A85]
|
[10] |
Ibrutinib |
DMHZCPO
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Ibrutinib. |
Mature B-cell lymphoma [2A85]
|
[10] |
Vincristine |
DMINOX3
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Vincristine. |
Mature B-cell lymphoma [2A85]
|
[10] |
Teniposide |
DMLW57T
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Teniposide. |
Mature B-cell lymphoma [2A85]
|
[10] |
Tisagenlecleucel |
DMM9BJD
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Tisagenlecleucel. |
Mature B-cell lymphoma [2A85]
|
[10] |
Mercaptopurine |
DMTM2IK
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Mercaptopurine. |
Mature B-cell lymphoma [2A85]
|
[10] |
Ponatinib |
DMYGJQO
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Ponatinib. |
Mature B-cell lymphoma [2A85]
|
[10] |
Cytarabine |
DMZD5QR
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Cytarabine. |
Mature B-cell lymphoma [2A85]
|
[10] |
Mechlorethamine |
DM0CVXA
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Mechlorethamine. |
Mature T-cell lymphoma [2A90]
|
[10] |
Dacarbazine |
DMNPZL4
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Dacarbazine. |
Melanoma [2C30]
|
[10] |
Ethinyl estradiol |
DMODJ40
|
Moderate |
Altered metabolism of Etanercept due to Ethinyl estradiol alters the formation of CYP450 enzymes. |
Menopausal disorder [GA30]
|
[12] |
Midazolam |
DMXOELT
|
Moderate |
Altered metabolism of Etanercept due to Midazolam alters the formation of CYP450 enzymes. |
Mood/affect symptom [MB24]
|
[8] |
Carfilzomib |
DM48K0X
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Carfilzomib. |
Multiple myeloma [2A83]
|
[10] |
Panobinostat |
DM58WKG
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Panobinostat. |
Multiple myeloma [2A83]
|
[10] |
Lenalidomide |
DM6Q7U4
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Lenalidomide. |
Multiple myeloma [2A83]
|
[10] |
Thalidomide |
DM70BU5
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Thalidomide. |
Multiple myeloma [2A83]
|
[10] |
Selinexor |
DMBD4K3
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Selinexor. |
Multiple myeloma [2A83]
|
[10] |
Belantamab mafodotin |
DMBT3AI
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Belantamab mafodotin. |
Multiple myeloma [2A83]
|
[10] |
Elotuzumab |
DMEYHG9
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Elotuzumab. |
Multiple myeloma [2A83]
|
[10] |
Daratumumab |
DMKCIUZ
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Daratumumab. |
Multiple myeloma [2A83]
|
[10] |
Bortezomib |
DMNO38U
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Bortezomib. |
Multiple myeloma [2A83]
|
[10] |
Melphalan |
DMOLNHF
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Melphalan. |
Multiple myeloma [2A83]
|
[10] |
Tecfidera |
DM2OVDT
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Tecfidera. |
Multiple sclerosis [8A40]
|
[10] |
Siponimod |
DM2R86O
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Siponimod. |
Multiple sclerosis [8A40]
|
[9] |
Ocrelizumab |
DMEZ2KH
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Ocrelizumab. |
Multiple sclerosis [8A40]
|
[10] |
Ozanimod |
DMT6AM2
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Ozanimod. |
Multiple sclerosis [8A40]
|
[8] |
Deflazacort |
DMV0RNS
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Deflazacort. |
Muscular dystrophy [8C70]
|
[10] |
Bexarotene |
DMOBIKY
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Bexarotene. |
Mycosis fungoides [2B01]
|
[10] |
Romidepsin |
DMT5GNL
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Romidepsin. |
Mycosis fungoides [2B01]
|
[10] |
Decitabine |
DMQL8XJ
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Decitabine. |
Myelodysplastic syndrome [2A37]
|
[10] |
Azacitidine |
DMTA5OE
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Azacitidine. |
Myelodysplastic syndrome [2A37]
|
[10] |
Nilotinib |
DM7HXWT
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Nilotinib. |
Myeloproliferative neoplasm [2A20]
|
[10] |
Ruxolitinib |
DM7Q98D
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Ruxolitinib. |
Myeloproliferative neoplasm [2A20]
|
[10] |
Imatinib |
DM7RJXL
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Imatinib. |
Myeloproliferative neoplasm [2A20]
|
[10] |
Dasatinib |
DMJV2EK
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Dasatinib. |
Myeloproliferative neoplasm [2A20]
|
[10] |
Hydroxyurea |
DMOQVU9
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Hydroxyurea. |
Myeloproliferative neoplasm [2A20]
|
[10] |
Omacetaxine mepesuccinate |
DMPU2WX
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Omacetaxine mepesuccinate. |
Myeloproliferative neoplasm [2A20]
|
[10] |
Busulfan |
DMXYJ9C
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Busulfan. |
Myeloproliferative neoplasm [2A20]
|
[10] |
Inebilizumab |
DMI0RHA
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Inebilizumab. |
Nervous system paraneoplastic/autoimmune disorder [8E4A]
|
[10] |
Atezolizumab |
DMMF8U0
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Atezolizumab. |
Non-small cell lung cancer [2C25]
|
[10] |
Olaparib |
DM8QB1D
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Olaparib. |
Ovarian cancer [2C73]
|
[10] |
Rucaparib |
DM9PVX8
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Rucaparib. |
Ovarian cancer [2C73]
|
[10] |
Carboplatin |
DMG281S
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Carboplatin. |
Ovarian cancer [2C73]
|
[10] |
Altretamine |
DMKLAYG
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Altretamine. |
Ovarian cancer [2C73]
|
[10] |
MK-4827 |
DMLYGH4
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and MK-4827. |
Ovarian cancer [2C73]
|
[10] |
Topotecan |
DMP6G8T
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Topotecan. |
Ovarian cancer [2C73]
|
[10] |
Buprenorphine |
DMPRI8G
|
Moderate |
Altered metabolism of Etanercept due to Buprenorphine alters the formation of CYP450 enzymes. |
Pain [MG30-MG3Z]
|
[8] |
Hydrocodone |
DMQ2JO5
|
Moderate |
Altered metabolism of Etanercept due to Hydrocodone alters the formation of CYP450 enzymes. |
Pain [MG30-MG3Z]
|
[8] |
Oxycodone |
DMXLKHV
|
Moderate |
Altered metabolism of Etanercept due to Oxycodone alters the formation of CYP450 enzymes. |
Pain [MG30-MG3Z]
|
[8] |
Streptozocin |
DMOF7AT
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Streptozocin. |
Pancreatic cancer [2C10]
|
[10] |
Levamisole |
DM5EN79
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Levamisole. |
Parasitic infection [1D0Y-1G2Z]
|
[10] |
Pemetrexed |
DMMX2E6
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Pemetrexed. |
Pleural mesothelioma [2C26]
|
[10] |
Prednisone |
DM2HG4X
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Prednisone. |
Postoperative inflammation [1A00-CA43]
|
[10] |
Hydrocortisone |
DMGEMB7
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Hydrocortisone. |
Postoperative inflammation [1A00-CA43]
|
[10] |
Brodalumab |
DMASDQ6
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Brodalumab. |
Psoriasis [EA90]
|
[10] |
Efalizumab |
DMCKL5V
|
Moderate |
Additive immunosuppressive effects by the combination of Etanercept and Efalizumab. |
Psoriasis [EA90]
|
[15] |
Infliximab |
DMH7OIA
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Infliximab. |
Psoriasis [EA90]
|
[10] |
Ustekinumab |
DMHTYK3
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Ustekinumab. |
Psoriasis [EA90]
|
[10] |
Tildrakizumab |
DMLW9HG
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Tildrakizumab. |
Psoriasis [EA90]
|
[10] |
Risankizumab |
DMM32GT
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Risankizumab. |
Psoriasis [EA90]
|
[10] |
Ixekizumab |
DMXW92T
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Ixekizumab. |
Psoriasis [EA90]
|
[10] |
Aldesleukin |
DM4YMIS
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Aldesleukin. |
Renal cell carcinoma [2C90]
|
[10] |
Everolimus |
DM8X2EH
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Everolimus. |
Renal cell carcinoma [2C90]
|
[10] |
Temsirolimus |
DMS104F
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Temsirolimus. |
Renal cell carcinoma [2C90]
|
[10] |
Fentanyl |
DM8WAHT
|
Moderate |
Altered metabolism of Etanercept due to Fentanyl alters the formation of CYP450 enzymes. |
Sensation disturbance [MB40]
|
[8] |
Sufentanil |
DMU7YEL
|
Moderate |
Altered metabolism of Etanercept due to Sufentanil alters the formation of CYP450 enzymes. |
Sensation disturbance [MB40]
|
[8] |
Anthrax vaccine |
DM9GSWY
|
Moderate |
Antagonize the effect of Etanercept when combined with Anthrax vaccine. |
Sepsis [1G40-1G41]
|
[16] |
Mogamulizumab |
DMISH0Z
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Mogamulizumab. |
Sezary syndrome [2B02]
|
[10] |
Floxuridine |
DM04LR2
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Floxuridine. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Dactinomycin |
DM2YGNW
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Dactinomycin. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Methylprednisolone |
DM4BDON
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Methylprednisolone. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Cyclophosphamide |
DM4O2Z7
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Cyclophosphamide. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Vinblastine |
DM5TVS3
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Vinblastine. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
PDX-101 |
DM6OC53
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and PDX-101. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Ifosfamide |
DMCT3I8
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Ifosfamide. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Docetaxel |
DMDI269
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Docetaxel. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Trabectedin |
DMG3Y89
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Trabectedin. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Mitoxantrone |
DMM39BF
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Mitoxantrone. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
LEE011 |
DMMX75K
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and LEE011. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Etoposide |
DMNH3PG
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Etoposide. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Epirubicin |
DMPDW6T
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Epirubicin. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Prednisolone |
DMQ8FR2
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Prednisolone. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Cisplatin |
DMRHGI9
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Cisplatin. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Gemcitabine |
DMSE3I7
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Gemcitabine. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Norethindrone |
DMTY169
|
Moderate |
Altered metabolism of Etanercept due to Norethindrone alters the formation of CYP450 enzymes. |
Solid tumour/cancer [2A00-2F9Z]
|
[12] |
Fluorouracil |
DMUM7HZ
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Fluorouracil. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Taxol |
DMUOT9V
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Taxol. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Doxorubicin |
DMVP5YE
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Doxorubicin. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Vinorelbine |
DMVXFYE
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Vinorelbine. |
Solid tumour/cancer [2A00-2F9Z]
|
[10] |
Warfarin |
DMJYCVW
|
Moderate |
Altered metabolism of Etanercept due to Warfarin alters the formation of CYP450 enzymes. |
Supraventricular tachyarrhythmia [BC81]
|
[8] |
Pomalidomide |
DMTGBAX
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Pomalidomide. |
Systemic sclerosis [4A42]
|
[10] |
Plicamycin |
DM7C8YV
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Plicamycin. |
Testicular cancer [2C80]
|
[10] |
Apixaban |
DM89JLN
|
Moderate |
Altered metabolism of Etanercept due to Apixaban alters the formation of CYP450 enzymes. |
Thrombosis [DB61-GB90]
|
[8] |
Dicumarol |
DMFQCB1
|
Moderate |
Altered metabolism of Etanercept due to Dicumarol alters the formation of CYP450 enzymes. |
Thrombosis [DB61-GB90]
|
[12] |
Trimetrexate |
DMDEA85
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Trimetrexate. |
Toxoplasmosis [1F57]
|
[10] |
Muromonab |
DM8ANCF
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Muromonab. |
Transplant rejection [NE84]
|
[10] |
Sirolimus |
DMGW1ID
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Sirolimus. |
Transplant rejection [NE84]
|
[10] |
Azathioprine |
DMMZSXQ
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Azathioprine. |
Transplant rejection [NE84]
|
[10] |
Mycophenolate mofetil |
DMPQAGE
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Mycophenolate mofetil. |
Transplant rejection [NE84]
|
[10] |
Basiliximab |
DMWNRZT
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Basiliximab. |
Transplant rejection [NE84]
|
[10] |
Belatacept |
DMXLYQF
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Belatacept. |
Transplant rejection [NE84]
|
[10] |
Durvalumab |
DM4PVDY
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Durvalumab. |
Ureteral cancer [2C92]
|
[10] |
Triamcinolone |
DM98IXF
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Triamcinolone. |
Vasomotor/allergic rhinitis [CA08]
|
[10] |
Disopyramide |
DM5SYZP
|
Moderate |
Altered metabolism of Etanercept due to Disopyramide alters the formation of CYP450 enzymes. |
Ventricular tachyarrhythmia [BC71]
|
[8] |
Mexiletine |
DMCTE9R
|
Moderate |
Altered metabolism of Etanercept due to Mexiletine alters the formation of CYP450 enzymes. |
Ventricular tachyarrhythmia [BC71]
|
[8] |
Procainamide |
DMNMXR8
|
Moderate |
Altered metabolism of Etanercept due to Procainamide alters the formation of CYP450 enzymes. |
Ventricular tachyarrhythmia [BC71]
|
[8] |
Propafenone |
DMPIBJK
|
Moderate |
Altered metabolism of Etanercept due to Propafenone alters the formation of CYP450 enzymes. |
Ventricular tachyarrhythmia [BC71]
|
[8] |
Flecainide |
DMSQDLE
|
Moderate |
Altered metabolism of Etanercept due to Flecainide alters the formation of CYP450 enzymes. |
Ventricular tachyarrhythmia [BC71]
|
[8] |
Amiodarone |
DMUTEX3
|
Moderate |
Altered metabolism of Etanercept due to Amiodarone alters the formation of CYP450 enzymes. |
Ventricular tachyarrhythmia [BC71]
|
[8] |
Ganciclovir |
DM1MBYQ
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Ganciclovir. |
Virus infection [1A24-1D9Z]
|
[10] |
Trifluridine |
DMG2YBD
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Trifluridine. |
Virus infection [1A24-1D9Z]
|
[10] |
Valganciclovir |
DMS2IUH
|
Major |
Additive immunosuppressive effects by the combination of Etanercept and Valganciclovir. |
Virus infection [1A24-1D9Z]
|
[10] |
----------- |
|
|
|
|
|